Discussion About Guidance of Diagnosis and Treatment of COVID-19 by Luobing Theory

Zhen-hua JIA

doi:10.13422/j.cnki.syfjx.20201146

您当前的位置：

首页 >

文章列表页 >

Discussion About Guidance of Diagnosis and Treatment of COVID-19 by Luobing Theory

Topic on Epidemic Resistance | 更新时间：2020-08-11

- Discussion About Guidance of Diagnosis and Treatment of COVID-19 by Luobing Theory
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 12, Pages: 18-22(2020)
- 作者机构：
  
  1.河北以岭医院，石家庄 050091
  2.络病研究与创新中药国家重点实验室，石家庄 050035
  3.国家中医药管理局重点研究室（心脑血管络病），石家庄 050035
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201146
  CLC： R2;R1;R254.3;Q939.4
- Published Online：26 February 2020，
  
  Published：20 June 2020
- 稿件说明：
移动端阅览
贾振华.络病理论指导新型冠状病毒肺炎证治探讨[J].中国实验方剂学杂志,2020,26(12):18-22.

JIA Zhen-hua.Discussion About Guidance of Diagnosis and Treatment of COVID-19 by Luobing Theory[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(12):18-22.
贾振华.络病理论指导新型冠状病毒肺炎证治探讨[J].中国实验方剂学杂志,2020,26(12):18-22. DOI： 10.13422/j.cnki.syfjx.20201146.

JIA Zhen-hua.Discussion About Guidance of Diagnosis and Treatment of COVID-19 by Luobing Theory[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(12):18-22. DOI： 10.13422/j.cnki.syfjx.20201146.

摘要

笔者应用络病理论指导新型冠状病毒肺炎证治研究，指出肺络包括气络与血络，是肺主气、司呼吸、朝百脉功能发挥的基础，气道与气络概念不同，但其功能与肺络密切相关。新型冠状病毒肺炎属中医“瘟疫”范畴，疫毒之邪由口鼻而入发病。疫毒袭肺、气道壅滞、邪盛正退、气络虚滞是该病早期特点，毒热内生、气道壅阻、“换气转血”功能失常是该病发展加重的关键环节，气病及血、血伤入络、耗血动血是该病后期转归。汲取历代医家瘟疫的治疗用药经验，提出早中期积极干预的治疗原则——首重病因、驱逐毒邪；先证用药、积极干预；整体调节、多靶治疗。以络病理论为指导研制的连花清瘟可以体外抑制新型冠状病毒活性，改善发热、咳嗽、乏力、气促等临床症状，减少疾病向重症发展的比率；连花清咳宣肺泄热、止咳化痰，可用于改善新型冠状病毒肺炎患者咳嗽咳痰症状，佐证了络病理论及通络药物在疫情防控中的重要科学价值。

Abstract

This paper uses the Luobing theory to guide the diagnosis and treatment of coronavirus disease-2019 (COVID-19)

and states that lung collateral includes Qi collateral and blood collateral

and is the basis for playing the function of lung of dominating Qi

controlling breathing and connecting all vessels. The concept of Qi channel is different from that of Qi collateral

but its function is closely related to lung collateral. COVID-19 belongs to "pestilence" in traditional Chinese medicine. The epidemic pathogenic factor enters from mouth and nose and then causes the disease. The early characteristics of this disease include the invasion of the lung by the epidemic pathogenic factor

the obstruction of Qi channels

the prevailing of the evil and the retreat of the good

and the deficiency and stagnation of Qi collateral. Generation of toxic heat from inside

obstruction of Qi channels and dysfunction of "breathing and blood transfer" are the key links to the development and aggravation of this disease. Qi disease involves blood

blood wound intrudes into collateral

and blood consumption and hemorrhage are the late outcome of this disease. Based on the experience of doctors of all dynasties in the treatment and medication of pestilence

the treatment principle of active intervention in the early and middle stage is proposed

including focusing on pathogenesis and expelling of toxin

drug use before syndrome onset and active intervention

and the whole regulation and multi-target treatment. Lianhua Qingwen developed under the guidance of Luobing theory can inhibit the activity of novel coronavirus

in vitro

relieve clinical symptoms (such as fever

cough

weakness

shortness of breath and so on) and reduce the rate of disease progression to severity. Lianhua Qingke can diffuse the lung

clear the lung heat

relieve cough and reduce sputum. It can be used to relieve the symptoms of cough and sputum in patients with COVID-19

which proves the important scientific value of Luobing theory and collateral-dredging drugs in epidemic prevention and control.

关键词

Keywords

references

吴以岭 . 络病理论体系构建及其学科价值 [J]. 前沿科学， 2007 ( 2 )： 40 - 46 .

吴以岭 . 中医络病学说与三维立体网络系统 [J]. 中医杂志， 2003 ， 44 ( 6 )： 407 - 409 .

吴以岭 . 气络—NEI网络相关性探析 [J]. 中医杂志， 2005 ， 46 ( 10 )： 723 - 726 .

熊露，石青，张玥 . 前列腺素E 1 对慢性肺源性心脏病合并心力衰竭患者心功能以及肺动脉压的影响 [J]. 临床合理用药杂志， 2015 ， 8 ( 4C )： 88 - 89 .

胡泉东，陈琼锋，曹畏 . 肾素-血管紧张素-醛固酮系统在肺部疾病作用中的研究进展 [J]. 南昌大学学报：医学版， 2019 ， 59 ( 1 )： 92 - 95 .

GUAN W J ， NI Z Y ， HU Y ， et al . Clinical characteristics of 2019 novel coronavirus infection in China [J]. MedRxiv ， 2020 ， doi： 10.1101/2020.02.06.20020974 http://dx.doi.org/10.1101/2020.02.06.20020974 .

XU Z ， SHI L ， WANG Y J ， et al . Pathological findings of COVID-19 associated with acute respiratory distress syndrome [J]. Lancet Resp Med ， 2020 ， doi： 10.1016/S2213-2600(20)30076-X http://dx.doi.org/10.1016/S2213-2600(20)30076-X .

ZHAO Y ， ZHAO Z X ， WANG Y J ， et al . Single-cell RNA expression profiling of ACE2，the putative receptor of Wuhan 2019-nCov [J]. BioRxiv ， 2020 ， doi： 10.1101/2020.01.26.919985 http://dx.doi.org/10.1101/2020.01.26.919985 .

刘映霞，杨扬，张聪，等 . 新型冠状病毒(2019-nCoV)感染患者肺损伤相关的临床及生化指标研究 [J]. 中国科学：生命科学， 2020 ， doi： 11.5840.Q.20200212.0801.006 http://dx.doi.org/11.5840.Q.20200212.0801.006 .

中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组 . 新型冠状病毒肺炎流行病学特征分析 [J]. 中华流行病学杂志， 2020 ， 42 ( 2 )： 145 - 151 .

国家卫生健康委员会，国家中医药管理局 . 新型冠状病毒肺炎诊疗方案（试行第六版） [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml ， 2020-02-19 / 2020-02-19 .

BIRD L . Calming the cytokine storm [J]. Nat Rev Immunol ， 2018 ， doi： 10.1038/s41577-018-0030-6 http://dx.doi.org/10.1038/s41577-018-0030-6 .

CHEN L ， LI M ， LIU Y P ， et al . Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) [J]. MedRxiv ， 2020 ， doi： 10.1101/2020.02.18.20024364 http://dx.doi.org/10.1101/2020.02.18.20024364 .

高占成 . 科学认识和科学管理是防控和救治新型冠状病毒肺炎的关键 [J]. 中华结核和呼吸杂志， 2020 ， doi： 10.3760/cma.j.issn.1001-0939.2020.0001 http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.0001 .

伍冬冬，潘频华，覃庆武 . 急性肺损伤/急性呼吸窘迫综合征发病机制研究进展 [J]. 中华结核和呼吸杂志， 2015 ， 38 ( 7 )： 524 - 527 .

朱名超，朱娅 . 新型冠状病毒肺炎的实验室检查及临床实验室的管理 [J]. 热带医学杂志， 2020 ， doi： 44.1503.R.20200220.1006.002 http://dx.doi.org/44.1503.R.20200220.1006.002 .

吴以岭，贾振华，常丽萍，等 . 脉络学说营卫理论指导血管病变防治研究 [J]. 中国实验方剂学杂志， 2019 ， 25 ( 1 )： 1 - 10 .

朱建辉 . 连花清瘟制剂临床应用与研究进展 [J]. 海峡药学， 2019 ， 31 ( 11 )： 200 - 202 .

莫红缨，柯昌文，郑劲平，等 . 连花清瘟胶囊体外抗甲型流感病毒的实验研究 [J]. 中药新药与临床药理， 2007 ， 18 ( 1 )： 5 - 9 .

佚名 . 中国军事医学科学院和北京地坛医院研究证实抗甲型H1N1流感病毒：中药连花清瘟胶囊取得重大突破 [J]. 中国处方药， 2009 ( 9 )： 41 .

中华人民共和国国家卫生和计划生育委员会 . 中东呼吸综合征病例诊疗方案（2015 年版） [J]. 中国病毒病杂志， 2015 ， 5 ( 5 )： 352 - 354 .

朱舜亚，李晓英，魏云玲，等 . 三种中药处方对SARS相关冠状病毒体外抑制作用的初步研究 [J]. 生物技术通讯， 2003 ， 14 ( 5 )： 390 - 392 .

DING Y W ， ZENG L J ， LI R F ， et al . The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function [J]. BMC Complement Altern Med ， 2017 ， 17 ： 130 .

DUAN Z P ， JIA Z H ， ZHANG J ， et al . Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial：a randomized，double blind，positive controlled clinical trial [J]. Chin Med J (Engl) ， 2011 ， 124 ( 18 )： 2925 - 2933 .

吕睿冰，王文菊，李欣 . 中药连花清瘟治疗新型冠状病毒肺炎疑似病例63例临床观察 [J]. 中医杂志， 2020 ， doi： 11.2166.R.20200215.1633.004 http://dx.doi.org/11.2166.R.20200215.1633.004 .

姚开涛，刘明瑜，李欣，等 . 中药连花清瘟治疗新型冠状病毒感染的肺炎回顾性临床分析 [J]. 中国实验方剂学杂志， 2020 ， doi： 10.13422/j.cnki.syfjx.20201099 http://dx.doi.org/10.13422/j.cnki.syfjx.20201099 .

程德忠，李毅 . 连花清瘟颗粒治疗54例新型冠状病毒肺炎患者临床分析及典型病例报道 [J]. 世界中医药， 2020 ， 15 ( 2 )： 150 - 154 .

贾振华，李红蓉，常丽萍，等 . 中医学应对疫病的历史回顾与思考 [J]. 中国实验方剂学杂志， 2020 ， doi： 10.13422/j.cnki.syfjx.20201071 http://dx.doi.org/10.13422/j.cnki.syfjx.20201071 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Historical Review and Reflection About Application of Traditional Chinese Medicine in Epidemic Diseases

Theoretical Exploration of Diabetic Retinopathy Guided by Luobing Theory

Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula

Theoretical Exploration of Cancer-related Fatigue in Malignant Tumors Guided by Luobing Theory

Visualized Analysis of Advances and Hot Spots of Lianhua Qingwen in Recent 10 Years

Related Author

LI Hong-rong

CHANG Li-ping

WEI Cong

JIA Zhen-hua

WEI Cong

JIA Zhenhua

MA Kun

MA Jing

Related Institution

Hebei Yiling Health Management Center

Hebei Yiling Pharmaceutical Research Institute

Key Laboratory of National Administration of Traditional Chinese Medicine（Cardiovascular and Cerebrovascular Luobing），Hebei Yiling Institute of Medicines

National Key Laboratory for Innovation and Transformation of Luobing Theory

National Key Laboratory of Collateral Disease Theory Innovation and Transformation， Hebei Institute of Integrated Chinese and Western Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰